新型ATP合成酶复合调节器MTA1通过驱动线粒体新陈代谢重编程来增强结肠癌肝脏转移
Ting Wang1,2, Fangzhou Sun2, Chunxiao Li2,3
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Molecular Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
转移相关抗原1 (MTA1) 通过增强氧化酸化 (OXPHOS) 来驱动结肠癌肝脏转移. 准MTA1和ATP合成酶可以提高药物敏感性,提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 分子生物学分子生物学
背景情况:
- 肝转移是结肠癌死亡率的一个关键因素.
- 沃伯格效应受到癌症中氧化酸化 (OXPHOS) 的增加的挑战,其机制尚不清楚.
- 目前正在研究转移相关抗原1 (MTA1) 在癌症进展中的作用.
研究的目的:
- 在结肠癌肝脏转移中识别线粒体生物能代谢的新型调节剂.
- 阐明MTA1影响氧化化 (OXPHOS) 和癌症进展的机制.
- 探索针对MTA1和线粒体通路的治疗策略,用于结肠癌治疗.
主要方法:
- 识别MTA1作为一种与ATP合成酶F1亚单元α (ATP5A) 相互作用的腺三酸盐 (ATP) 合成酶调节器.
- 评估MTA1在线粒体生物能代谢重编程和OXPHOS增强中的作用.
- 在异种移植模型和临床病例中进行高通量药物查和验证.
主要成果:
- 通过ATP合成酶调节,MTA1通过增强OXPHOS促进结肠癌肝脏转移.
- MTA1淘汰赛使结肠癌细胞对向线粒体代谢和mTOR抑制剂的药物敏感.
- 抑制ATP5A增强肝转移结肠癌中对西罗的敏感性,依赖于MTA1.
结论:
- 在癌症转移中,MTA1是线粒体生物能量重编程的新型调节器.
- 由MTA1主导的线粒体OXPHOS的升级,代表了转移中华堡效应的逆转.
- 准MTA1和ATP5A为治疗结肠癌肝转移提供了一个有希望的治疗途径.
更多相关视频
11:43Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
10:26Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
Published on: October 21, 2022
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
PI3K/mTOR/AKT Signaling Pathway
